Hypodermoclysis for symptom control in terminal care.

Area of Science:

• Palliative Care
• Geriatrics
• Clinical Pharmacology

Background:

• Subcutaneous fluid and electrolyte infusions, or hypodermoclysis (HDC), are utilized for fluid replacement and correcting imbalances.
• The Palliative Care Unit at Edmonton General Hospital has employed HDC since 1982 for symptom management.
• HDC is considered when the oral route for medication or hydration is no longer feasible.

Purpose of the Study:

• To evaluate the efficacy of hypodermoclysis (HDC) for symptom control in terminal patients.
• To compare HDC with alternative administration routes in palliative care settings.

Main Methods:

• Utilizing hypodermoclysis (HDC) for fluid and electrolyte replacement and symptom control.
• Titrating infusion rates based on symptom severity.
• Employing dual-site HDC for simultaneous or differentially-paced drug administration when necessary.

Main Results:

• Hypodermoclysis (HDC) provides adequate symptom control for patients in terminal phases of illness.
• HDC demonstrates advantages compared to intravenous, intermittent subcutaneous, intramuscular, and rectal routes of administration.

Conclusions:

• Hypodermoclysis (HDC) is a viable and advantageous method for symptom management in palliative care.
• The described HDC method offers benefits over alternative routes for fluid and medication delivery in end-of-life care.